Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer;Duración del tratamiento adyuvante con tamoxifeno en el cáncer de mama operable

Revista Medica de Chile

Volumn 126, Issue 2, 1998, Pages 210-217

  Davies, Christina ^a   Arriagada I, Rodrigo ^b   Ziegler B, Annemarie ^c   Peralta M, Octavio ^c  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b Instituto de Radiomedicina Santiago   (Chile)

^c NONE

Author keywords

Breast neoplasms; Surgery, operative; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; FOLLOW UP; HUMAN; REVIEW; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 3242866362     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. LIPPMAN ME, BOLAN G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 1975; 256: 592-3.
2. FURR BJA, JORDAN VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
3. EARLY BREAST Cancer Trialists' Collaborative Group (EBCTCG). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15 y 71-85.
4. CHU KC, TARONE RE, KESSLER LG ET AL. Recent trends in US breast cancer incidence, survival and mortality rates. J Natl Cancer Inst 1996; 88: 1571-80.
5. BERAL V, HERMON C, REEVES G, PETO R. Sudden fall in breast cancer death rates in England and Wales. Lancet 1995; 345: 1642-3.
6. POWLES T, TICKISH T, KANIS JA ET AL. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptiometry in healthy premenopausal and post-menopausal women. J Clin Oncol 1996; 14: 78-84.
7. LOVE RR, MAZESS RB, BARDEM HS ET AL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-6.
8. KRISTENSEN B, EJLERSTEN B, DALGAARD P ET AL. Tamoxifen and bone metabolism in post-menopausal low risk breast cancer patients. A randomized study. J Clin Oncol 1994; 12: 992-7.
9. GUETTA V, LUSH RM, FIGG WD ET AL. Effects of the antioestrogen Tamoxifen on low density lipoprotein concentrations and oxidation in post-menopausal women. Am J Cardiol 1995; 76: 1072-3.
10. MCDONALD CC, STEWART HJ, FOR THE SCOTTISH BREAST CANCER COMMITTEE. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. BMJ 1991; 303: 435-7.
11. NAYFIELD SG, GONN MB. Tamoxifen-associated eye-disease. A review. J Clin Oncol 1996; 14: 1018-26.
12. RUTQVIST LE, MATTSSON A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomised trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398-1406.
13. PRITCHARD KI, PATERSON AHG, PAUL NA ET AL. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14: 2731-7.
14. FORNANDER T, RUTQVIST LE, CEDERMARK B ET AL. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-20.
15. NAYFIELD SG, KARP SE, FORD LG ET AL. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450-9.
16. SWEDISH BREAST CANCER CO-OPERATIVE GROUP. Randomized trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal early-stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-9.
17. CURRENT TRIALS WORKING PARTY OF THE CANCER RESEARCH CAMPAIGN BREAST CANCER TRIALS GROUP. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834-9.
18. FISHER BV, DIGNAM J, BRYANT J ET AL. The worth of 5 versus more than 5 years of tamoxifen therapy for breast cancer patients with negative nodes and estrogen-receptor positive tumors: an update of NSABP B-14. J Natl Cancer Inst 1996; 88: 1529-42.
19. TORMEY DC, GRAY R, FALKSON HC (FOR THE EASTERN CO-OPERATIVE ONCOLOGY GROUP). Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996; 88: 1828-33.
20. STEWART HJ, FORREST AP, EVERINGTON D ET AL. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer 1996; 74: 297-9.
21. LOVE RR, WIEBE DA, NEWCOMB PA ET AL. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-4.
22. FORNANDER T, HELLSTROM AC, MOBERGER B. Descriptive clinicopathological study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993; 85: 1850-5.
23. ANDERSSON M, STORM H, MOURIDSEN H. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncológica 1992; 31: 259-63.
24. FISHER B, CONSTANTINO JP, REDMOND CK ET AL. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel projects (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
25. WILLIAMS GM, IATROPOULOS MJ, DJORDJEVIC MV ET AL. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 7: 315-7.
26. PAVLIDIS M, PETRIS C, BRIASSOULIS E. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992; 69: 2901-4.
27. JONES SE, CATHCAT C, PUMRAY S ET AL. Frequency, severity, and management of tamoxifen induced depression in women with node-negative breast cancer. Proc ASCO 1993; 12: 78 (abst 112).
28. WHO IARC PRESS RELEASE. IARC Evaluates the carcinogenic risk associated with Tamoxifen. Feb. 1996.
29. COLLINS R, PETO R, GRAY R, PARISH S. Large scale randomised evidence: trials and overviews. En: Oxford Textbook of Medicine (3rd edition, 1996), ed. Weatherall DJ, Ledingham JGG, Warrell DA. Oxford: Oxford University Press, 1996.
30. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP (EBCTCG). Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988; 319: 1681-92.
31. SWAIN S. Editorial: Tamoxifen: the Long and Short of It. J Natl Cancer Inst 1996; 88: 1510-3.
32. PETO R. Editorial: Five years of tamoxifen - or more? J Natl Cancer Inst 1996; 88: 1791-3.
33. ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) protocol. ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) protocol.